Doctors are always trying to improve the diagnosis and treatment of cancer.
Small cell prostate cancer clinical trials.
Cancer vaccine targets under evaluation in prostate cancer clinical trials include.
Nci s basic information about clinical trials explains the types and phases of trials and how they are carried out.
Clinical trials look at new ways to prevent detect or treat disease.
Subjects will be treated with mln8237 at 50 mg twice daily for 7 days repeated every 21 days.
But small cell prostate cancer is very rare so it is harder to research than other more common types of prostate cancer.
The purpose of this research study is to assess the impact of 68ga psma 11 pet ct an experimental imaging scan for prostate cancer on the success of.
The clinical trials on this list are for prostate cancer treatment.
Non small cell lung cancer or prostate cancer that has spread to other.
Not all neuroendocrine prostate cancers carry the same prognosis.
Progression during or following completion of at least 1 prior line of systemic therapy for locally advanced or metastatic prostate cancer.
The eligibility criteria which is meant to ensure patients safety may include the patient s age gender cancer type and stage previous treatments and overall health.
Clinical trials also known as clinical studies or research protocols are conducted to test whether a new drug new prevention strategy or new screening test is safe and effective in people.
This is a multi institutional single arm open label phase 2 trial evaluating mln8237 in patients with histologically confirmed or clinically suspected metastatic neuroendocrine prostate cancer.
An antigen often expressed by several different types of cancers cea.
Although all clinical trials have criteria for the participants clinical trials are available to patients at all stages of cancer.
All trials on the list are supported by nci.
Clinical trials are research studies that involve people.
The proposed clinical trial will study the effects of 12 months of therapy with arn 509 alone or in combination with an lhrh agonist lhrha each compared to lhrha alone in men with a rapidly rising serum psa after prior definitive local therapy for prostate cancer.
Patients with de novo small cell prostate cancer are not required to have received androgen deprivation therapy adt.
A clinical research study is now enrolling men with recurrent prostate cancer after radical prostatectomy who have a psa of at least 0 1 ng ml and are planned to undergo salvage radiotherapy.
Participation is always voluntary.
Research and clinical trials.
